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Summary
Background: Polyunsaturated fatty acids (PUFA) have been related to the develop-
ment of adiposity. N-3 PUFA appears to be protective against obesity risk, while n-6
PUFA may be associated with greater adiposity. However, most studies have been
conducted among adults. The role of PUFA in infancy is unknown.
Objective: To examine associations of serum PUFA at age 1 year with age- and sex-
adjusted body mass index Z score (BMIZ) change through age 16 years and body
composition at 16 years.
Methods: We quantified serum PUFA in 636 Chilean infants aged 1 year. We
measured BMIZ at ages 1, 5, 10 and 16 years, and body composition by dual energy
X-ray absorptiometry at 16 years. We estimated differences in 1- to 16-years BMIZ
change between PUFA quartiles from multivariable linear mixed models with
restricted cubic splines. At 16 years, we estimated differences in total fat mass
(ToFM), truncal fat mass (TrFM), total lean mass (TLM), percent total fat mass
(%ToFM) and percent truncal fat mass (%TrFM) between PUFA quartiles using linear
regression.
Results: PUFA were not associated with BMIZ change. Alpha-linolenic acid (ALA)
was positively associated with TrFM (P = .03) and %TrFM (P < .0001) at 16 years
while eicosapentaenoic acid (EPA) was inversely associated with %TrFM (P = .001).
Docosapentaenoic acid (DPA) was positively associated with ToFM (P = .01), TrFM
(P = .009), %ToFM (P = .02) and %TrFM (P = .02). Gamma-linolenic acid (GLA) and the
Δ6-desaturase (D6D) activity index were each positively, linearly associated with
ToFM, TrFM and %ToFM. The Δ5-desaturase (D5D) activity index was inversely
associated with %TrFM (P = .04).
Abbreviations: %ToFM, percent total fat mass; %TrFM, percent truncal fat mass; AA, arachidonic acid; ALA, alpha-linolenic acid; BMI, body mass index; BMIZ, BMI-for-age Z score; CI,
confidence interval; D5D, Δ5-desaturase; D6D, Δ6-desaturase; DGLA, dihomo-gamma-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; DXA, dual energy X-ray
absorptiometry; EPA, eicosapentaenoic acid; FA, fatty acids; GLA, gamma-linolenic acid; IDA, iron deficiency anaemia; INTA, University of Chile Institute of Nutrition and Food Technology; LA,
linoleic acid; PUFA, polyunsaturated fatty acids; SES, socioeconomic status; TLM, total lean mass; ToFM, total fat mass; TrFM, truncal fat mass.
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Conclusions: ALA, DPA, GLA and the D6D index at 1 year of age were positively
associated with adiposity at age 16 years, while EPA and the D5D index were
inversely associated with central adiposity. Our results related to EPA and desaturase
indices are in agreement with limited prior studies.
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1 | INTRODUCTION
Childhood obesity is the most prevalent early life risk factor for the
development of chronic diseases, including type 2 diabetes, hyperten-
sion and coronary heart disease.1 Childhood obesity has increased
globally throughout recent decades2 and represents a significant pub-
lic health concern. Identifying potentially modifiable nutritional expo-
sures that influence the early development of adiposity is crucial in
order to address this epidemic.
Polyunsaturated fatty acids (PUFA) are nutrients that may be
related to the etiology of obesity. These fatty acids (FA), primarily
classified into the n-3 and n-6 families, are necessary for a variety of
physiologic processes. In particular, long-chain PUFA are precursors
for eicosanoids, signalling molecules that regulate cardiovascular and
immune function. In animal and in vitro studies, both plant- and
marine-derived n-3 PUFA reduce or prevent adiposity, through reduc-
tion of fat deposition in adipose tissue and appetite suppression.3,4
Conversely, n-6 PUFA up-regulate adipocyte size and number.5 Stud-
ies of PUFA and adiposity among adult humans have yielded mixed
results. Some, but not all, trials of n-3 PUFA supplementation have
found an inverse effect on adiposity.6 While several observational
studies (reviewed by Naughton et al7) report a positive association
between the n-6 PUFA linoleic acid (18:2 n-6; LA) and body weight, a
meta-analysis of n-6 PUFA supplementation trials did not find strong
evidence for an effect of these PUFA on adiposity.8
PUFA status in infancy may be particularly influential on future
adiposity. The precursor PUFA alpha-linolenic acid (18:3 n-3; ALA)
and LA cannot be synthesized endogenously, and their conversion
into long-chain PUFA is inefficient in humans.9 Thus, infants must
largely obtain these FA through diet, initially from breast milk or for-
mula10 and later through complementary feeding. Nutrition during
infancy can have long-term effects on cardiovascular health.11 Adi-
pose tissue in childhood may be especially sensitive to the effects of
PUFA, since this is the time during which the number of adipocytes in
the body is determined.12 Most previous investigations of early-life
PUFA and adiposity have focused on exposure in utero.13 The poten-
tial effects of PUFA in infancy may differ from those in utero, but
results from previous studies have been inconclusive, and little
research exists on measures of long-term adiposity. In a recent review
of both observational studies and trials of n-3 PUFA supplementation
in infancy, results were a mix of positive, inverse and null associations
of specific PUFA with measures of adiposity through middle child-
hood.13 In addition to these inconclusive findings, the outcomes in
these studies were assessed at ages 6 to 8 years, and thus it is still
unclear whether PUFA might have longer-reaching effects on adipos-
ity throughout development. Moreover, very few studies have been
conducted in low- and middle-income countries,14-16 despite the rap-
idly growing burden of childhood obesity2 and low availability of die-
tary PUFA17 affecting many of these regions.
We aimed to investigate the relations between serum PUFA bio-
markers at 1 year of age and measures of adiposity at age 16 years in
a cohort of children from Santiago, Chile.
2 | METHODS
2.1 | Study design and population
We conducted a longitudinal investigation among Chilean children
who were enrolled as infants in studies on iron status and were
followed through adolescence. Details of the study design have
been published previously.18,19 Briefly, participants were recruited
at ages 4 to 6 months from low- and middle-income communities in
Santiago, Chile between 1991 and 1996. Eligible infants were sin-
gleton, born at term weighing at least 3 kg through uncomplicated,
vaginal births, and did not have major health complications. Infants
without iron deficiency anaemia (IDA) at baseline were enrolled in a
trial of iron supplementation. These participants were randomly
assigned to high- or low-dose iron supplementation or usual nutri-
tion until 12 months of age. Infants with IDA were treated with iron
and enrolled in an observational study of neurodevelopment, along
with a group of non-anaemic controls. There were 1798 infants
enrolled. The cohort was followed during middle childhood and ado-
lescence: 888 children were assessed at 5 years of age, 1127 at
10 years of age and a subset of 679 were assessed at a median age
of 16.8 years of age as part of a study on cardiometabolic risk.20
The study of FA was conducted among participants who had a
stored serum sample available from age 1 year plus at least one
more sample from ages 5 or 10 years. For analyses of BMIZ change
between 1 and 16 years of age, we included 636 children in the FA
study who had BMIZ data available at 1 year of age and at ≥1 subse-
quent assessment (5, 10 or 16 years of age). For the analysis of
PUFA at 1 year of age and DXA measures of body composition at
16 years of age, there were 382 children with available information.
A flowchart of the sample size at each inclusion step is provided in
Figure S1.
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The study procedures were approved by institutional review
boards at the University of Chile Institute of Nutrition and Food Tech-
nology (INTA), the University of Michigan and the University of Cali-
fornia, San Diego. Parents provided written informed consent to
participate for their children, and children provided assent beginning
at 10 years of age.
2.2 | Data collection
Birth weight in g, length in cm and gestational age in weeks were
determined via hospital records. The date of the mother's last men-
strual period was used to determine gestational age. Study personnel
collected information from parents on household socioeconomic indi-
cators at enrollment. Information on breastfeeding habits, including
the date of the first bottle feeding and last breastfeeding, were col-
lected from mothers at weekly study visits that took place from enroll-
ment until the infant was 12 months old. For infants who had already
been bottle fed at enrollment, mothers were asked to recall the date
of the first bottle feeding. Because feeding breast milk by bottle was
non-existent in this population, bottle feeding was equivalent to giv-
ing infant formula or cow milk.
Anthropometric measurements were collected at INTA by trained
study personnel using standardized techniques. At 1 year of age,
weight was measured unclothed to the nearest 10 g and length was
measured to the nearest millimetre using a recumbent length board.
Weight at 5, 10 and 16 years was measured to the nearest 100 g
using a Seca scale (Seca, Hamburg, Germany) and height was mea-
sured to the nearest millimetre using a Holtain stadiometer (Holtain,
Crymych, UK). All measures were obtained in duplicate and a third
measurement was taken if the difference between the first two was
greater than 0.3 kg or 0.5 cm; the mean of the two closest values was
used. At the 16.8-year assessment, total fat mass, truncal fat mass
and total lean mass were measured with a dual energy X-ray absorpti-
ometry (DXA) instrument (Lunar Prodigy Corp., Madison, WI, USA).
These measures were conducted in the subset of children who partici-
pated in the study of cardiometabolic risk.
A blood sample was collected by venipuncture at 1, 5 and
10 years of age. The median (25th, 75th percentile) age at the 1 year
blood draw was 1.00 year (0.99, 1.02). Blood components were sepa-
rated and serum samples from 1 year of age were stored at −80C
before transportation as a single batch to the University of Michigan
where they were cryostored at −80C and analyzed after approxi-
mately 20 years from collection. Serum PUFA stored at −80C are
highly stable. A previous study found virtually no degradation of
PUFA in samples stored at −80C for up to 10 years.21
2.3 | Fatty acid analyses
FA in serum were quantified at the University of Michigan Regional
Comprehensive Metabolomics Resource Core. Total lipids were
extracted from 200 μL of serum according to the method described
by Bligh and Dyer.22 10 μL of 4 mM nonadecanoic acid (C19:0) was
used as the internal standard. The FA fraction of the total lipids was
derivatized into methyl esters using BF3-methanol as previously
described.23 These were extracted with a 2:1 hexane-water, dried and
resuspended in hexane. FA were measured using gas chromatography.
1 to 2 μL of sample was injected via autosampler onto an Agilent
6890 N chromatograph (Agilent, Santa Clara, CA, USA) with a flame
ionization detector, a 100 m x 0.25 mm × 0.2 μm SP-2560 column
(Sigma-Aldrich, Bellefonte, PA) and Chemstation software. C19:0 and
other authentic methyl esters were used to create a calibration curve
for FA quantification. The authentic methyl esters were also used to
identify FA in samples based on retention times. The coefficients of
variation for quantification of specific FA ranged between 2.5%
and 3.6%.
2.4 | Statistical analyses
2.4.1 | Definition of exposures
The main exposures were serum PUFA biomarkers measured at 1 year
of age, expressed as percentage relative to the total FA concentration
(FA %) quantified in a sample. The n-3 PUFA we considered were
ALA, eicosapentaenoic acid (20:5 n-3; EPA), docosapentaenoic acid
(22:5 n-3; DPA) and docosahexaenoic acid (22:6 n-3; DHA). N-6
PUFA included LA, gamma-linolenic acid (18:3 n-6; GLA), dihomo-
gamma-linolenic acid (20:3 n-6; DGLA) and arachidonic acid (20:4 n-6;
AA). We also considered the ratio of total n-6:n-3 PUFA, which may
be important for adiposity development.24 Additionally, we consid-
ered activity indices of the Δ6-desaturase (D6D) and Δ5-desaturase
(D5D) enzymes, using the GLA/LA and AA/DGLA ratios, respectively.
We categorized all exposures into quartiles to allow for possible non-
linear associations with the outcomes.
2.4.2 | Definition of outcomes
The primary outcomes were change in age- and sex-adjusted body
mass index (BMI) Z scores (BMIZ) between 1 and 16 years of age and
DXA measures of body composition at 16 years of age. BMI was cal-
culated as kg/m2 and BMIZ were calculated according to the World
Health Organization Growth Reference for children ages 5 to
19 years.25 DXA measures included the total fat mass (ToFM),
truncal fat mass (TrFM), total lean mass (TLM), percent total fat mass
(%ToFM) and percent truncal fat mass (%TrFM).
2.4.3 | Covariates
All covariates were measured in infancy and included sociodemo-
graphic and anthropometric characteristics as well as serum FA.
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We categorized birth length and weight as average or large for ges-
tational age according to the INTERGROWTH 21st standards for
newborn size.26 We defined large for gestational age as ≥90th per-
centile. We did not consider a category of small for gestational age
because birth weight ≥ 3 kg was an eligibility criterion for recruit-
ment and there were no children ≤10th percentile for birth weight.
Seven children with birth length ≤10th percentile were classified
in the average for gestational age group. We categorized
breastfeeding as <6 months, ≥6 months mixed bottle/breastfeeding,
or ≥ 6 months exclusive breastfeeding. Iron supplementation was
categorized as any (combining low- and high-dose groups) vs none.
We measured socioeconomic status (SES) using a modified Graffar
index.27 The index consists of 13 items related to family structure,
education and employment, crowding and housing condition and
ownership of assets. The index ranges from 0 to 65; higher values
indicate lower SES. The serum FA that we considered as covariates
were total trans FA, which have been associated with weight gain in
adults.28
2.4.4 | Correlates of serum PUFA at 1 year of age
We compared distributions of serum PUFA biomarkers by categories
of covariates using means ± SD. We tested the significance of associa-
tions using linear regression models with each PUFA biomarker as the
outcome. For dichotomous covariates, we obtained P values from
Wald tests. For ordinal variables, we tested for linear trends using
Wald tests of a variable representing category-specific medians intro-
duced as a continuous variable. For categorical covariates, we used a
χ2 score statistic.
2.4.5 | Serum PUFA at 1 year of age and change in
BMIZ from ages 1 to 16 years
In bivariate analysis, we estimated means ± SE of BMIZ at 1 and
16 years of age and change in BMIZ between 1 and 16 years by
quartiles of the PUFA exposures at age 1 year. These were from
BMIZ growth curves estimated using mixed effects linear regres-
sion models.29 The outcome was BMIZ and age was included as a
predictor using restricted cubic splines.30 These piecewise cubic
polynomials are smoothly joined at each knot and linear in the
tails. They allow for modelling of smoothed, non-linear trajectories
of BMIZ across different ages. These methods do not require that
all children have the same number of measurements or that the
measurements be obtained at the same ages. Thus, we fitted the
models with data from all assessments (1, 5, 10 and 16 years) and
placed knots at the median ages of children measured at each
assessment. Other predictors in the model included indicator vari-
ables for each PUFA quartile, interaction terms between the PUFA
indicators and all age terms and random intercepts and age slopes
for each child. We estimated adjusted mean differences and 95%
confidence intervals (CI) in 1 to 16 years BMIZ change between
quartiles of serum PUFA from these models. We included
covariates that were associated with the PUFA biomarkers or that
have been related to BMIZ change. The final model included sex,
birth weight, breastfeeding, Graffar index and total serum trans FA
at 1 year of age. Each long-chain PUFA was adjusted for its imme-
diate metabolic precursor: EPA was adjusted for ALA, DPA for
EPA, DHA for DPA, GLA for LA, DGLA for GLA and AA for DGLA.
In order to adjust for potential confounding by common dietary
sources of n-3 and n-6 PUFA, which co-occur as LA and ALA in
foods such as plant oils,31 we adjusted estimates for each n-3
PUFA for LA and total long-chain n-6 PUFA, while estimates for
each n-6 PUFA were adjusted for ALA and total long-chain n-3
PUFA. All covariate FA were entered in the model as restricted
cubic splines in order to account for possible residual confounding
due to non-linear associations with the outcome. When the associ-
ation between PUFA quartiles and BMIZ change seemed linear, we
estimated the difference in change per 1 SD of the PUFA
distribution.
2.4.6 | Serum PUFA at 1 year of age and body
composition at 16 years
In bivariate analysis, we compared distributions of ToFM, TrFM, TLM,
%ToFM and %TrFM by quartiles of serum PUFA using means ±
SD. We conducted tests for linear trend using linear regression
models with each body composition measure as the outcome and a
variable representing median values of each PUFA quartile introduced
as a continuous variable. In multivariable analysis we obtained
adjusted mean differences and 95% CI in the body composition mea-
sures by quartiles of serum PUFA. These models included indicators
for PUFA quartiles and were also adjusted for sex, birth weight,
breastfeeding, Graffar index, BMI at 1 year of age and total serum
trans FA. We also included other PUFA as covariates following the
strategy described for the analyses of BMIZ change. Because body
composition may differ by sex in adolescence, we conducted supple-
mental analyses stratified by sex by including interaction terms
between sex and all other model predictors and testing for their statis-
tical significance.
We fitted all models with empirical variance estimates, which are
robust to heteroskedasticity and deviations from normality.32 All ana-
lyses were conducted using Statistical Analysis Software version 9.4
(SAS Institute, Cary, NC).
3 | RESULTS
The number of children with 2, 3 or 4 measurements was 78, 183 and
375, respectively. Mean ± SD BMIZ at 1, 5, 10 and 16 years of age
was 0.81 ± 0.94, 0.98 ± 1.18, 1.02 ± 1.16 and 0.71 ± 1.13, respec-
tively. At age 16 years, mean ± SD ToFM, TrFM and LM was
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19.8 ± 10.1, 10.0 ± 5.7 and 44.0 ± 8.9 kg, respectively. Mean ± SD %
ToFM and %TrFM was 29.1 ± 10.9 and 49.3 ± 5.9.
3.1 | N-3 PUFA
3.1.1. | Correlates of n-3 PUFA at 1 year
Serum ALA was positively associated with iron supplementation
(Table S1). EPA was positively related to exclusive breastfeeding dura-
tion and total trans FA. DPA was inversely associated with iron supple-
mentation. DHA was related to female sex and exclusive breastfeeding
duration, and inversely associated with total serum trans FA.
3.1.2. | BMIZ change between ages 1 and 16 years
N-3 PUFA at 1 year of age were not significantly associated with
BMIZ change from 1 to 16 years (Table 1 and Table S2).
3.1.3. | Body composition at age 16 years
ALA was positively associated with TrFM and %TrFM in non-linear
fashions (Table 2 and Table S2). Adjusted mean differences (95% CI)
between children with ALA in quartile (Q) 4 vs <Q4 were 1.5 kg (0.2,
2.8; P = .03) for TrFM and 3.3 percentage points (95% CI: 2.0%, 4.6%;
P < .0001) for %TrFM. EPA was inversely associated with %TrFM
TABLE 1 Changes in BMI-for-age Z scores (BMIZ)a from 1 to 16 years of age by serum n-3 polyunsaturated fatty acid biomarkers at 1 year
of age among children from Santiago, Chile
Fatty acid quartile (median,









Overall 636 0.81 ± 0.04 0.72 ± 0.05 −0.09 ± 0.05
N-3
ALA (18:3 n-3)
Q1 (0.21) 159 0.81 ± 0.07 0.68 ± 0.09 −0.13 ± 0.11 Reference
Q2 (0.28) 159 0.73 ± 0.07 0.61 ± 0.09 −0.12 ± 0.10 −0.01 (−0.30, 0.27)
Q3 (0.39) 159 0.88 ± 0.08 0.76 ± 0.09 −0.12 ± 0.10 −0.04 (−0.33, 0.25)
Q4 (1.32) 159 0.84 ± 0.08 0.83 ± 0.09 −0.01 ± 0.10 0.06 (−0.24, 0.36)
P, trendd .33 .55
EPA (20:5 n-3)
Q1 (0.07) 159 0.78 ± 0.07 0.65 ± 0.09 −0.12 ± 0.10 Reference
Q2 (0.13) 159 0.80 ± 0.07 0.80 ± 0.09 0.00 ± 0.10 0.10 (−0.18, 0.38)
Q3 (0.22) 159 0.81 ± 0.07 0.77 ± 0.09 −0.05 ± 0.10 0.07 (−0.21, 0.35)
Q4 (0.34) 159 0.86 ± 0.08 0.66 ± 0.09 −0.20 ± 0.11 −0.06 (−0.35, 0.23)
P, trend .46 .56
DPA (22:5 n-3)
Q1 (0.08) 160 0.78 ± 0.07 0.48 ± 0.09 −0.30 ± 0.09 Reference
Q2 (0.11) 158 0.78 ± 0.07 0.72 ± 0.09 −0.05 ± 0.10 0.23 (−0.04, 0.50)
Q3 (0.14) 159 0.75 ± 0.07 0.98 ± 0.09 0.23 ± 0.10 0.54 (0.26, 0.82)
Q4 (0.21) 159 0.94 ± 0.08 0.71 ± 0.09 −0.24 ± 0.11 0.07 (−0.21, 0.35)
P, trend .75 .71
DHA (22:6 n-3)
Q1 (0.23) 158 0.84 ± 0.08 0.67 ± 0.10 −0.17 ± 0.10 Reference
Q2 (0.43) 160 0.87 ± 0.06 0.69 ± 0.09 −0.17 ± 0.10 0.05 (−0.23, 0.33)
Q3 (0.62) 159 0.71 ± 0.07 0.72 ± 0.09 0.01 ± 0.10 0.20 (−0.11, 0.50)
Q4 (0.90) 159 0.83 ± 0.08 0.80 ± 0.09 −0.03 ± 0.10 0.17 (−0.16, 0.50)
P, trend .19 .28
aAccording to the World Health Organization Growth Reference for children ages 5 to 19 years.25
bFrom growth curves estimated using mixed effects linear regression models with BMIZ as the outcome, and predictors that included indicator variables
for each PUFA quartile, linear and cubic spline terms for age, and interaction terms between the quartiles and age terms. All models included random inter-
cepts and age slopes to account for within-child correlations of repeated BMI measurements.
cAdjusted for sex, birth weight (large vs average for gestational age), breastfeeding (<6 months, ≥6 months w/ bottle feeding, ≥6 months exclusive), Graffar
index (indicator variables for quintiles) and total serum trans fatty acids (FA). All n-3 PUFA are adjusted for LA and total long-chain n-6 PUFA. All long chain
PUFA are adjusted for their precursor PUFA. Covariate FA are represented with linear and restricted cubic spline terms.
dFrom mixed effects linear regression models with BMI as the outcome and a variable representing medians of PUFA quartiles introduced as continuous.
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(adjusted mean difference >Q1 vs Q1: −2.1%; 95% CI: −3.5%, −0.9%;
P = .001). DPA was positively associated with fat mass indices in non-
linear manners. Adjusted mean differences (95% CI) between
DPA > Q1 vs Q1 for ToFM, TrFM, %ToFM and %TrFM were, respec-
tively, 2.7 kg (95% CI: 0.7, 4.8; P = .01), 1.6 kg (95% CI: 0.4, 2.8;
P = .009), 2.3% (95% CI: 0.4, 4.2; P = .02) and 1.8% (95% CI: 0.3, 3.2;
P = .02). Most associations did not differ by sex (Tables S3 and S4).
However, the positive association of ALA with %TrFM was stronger
among boys (P, interaction = .02), as was the inverse association of
EPA with %TrFM (P, interaction = .004).
3.2 | N-6 PUFA
3.2.1 | Correlates of n-6 PUFA at 1 year
LA was positively associated with exclusive breastfeeding ≥6 months
and with iron supplementation (Table S5). It was inversely associated
with total trans FA. Serum GLA was inversely related to length-for-
gestational age and socioeconomic status. DGLA was positively asso-
ciated with length- and weight-for-gestational age and inversely
related to iron supplementation. AA was positively associated with
length- and weight-for-gestational age, and exclusive breastfeeding
≥6 months, and inversely related to iron supplementation and total
trans FA. The n-6:n-3 ratio was inversely associated with total trans
FA. The D6D index was inversely associated with length-for-
gestational age and socioeconomic status.
3.2.2 | BMIZ change between ages 1 and 16 years
Neither n-6 PUFA, the n-6:n-3 ratio, nor desaturase indices at 1 year
of age were significantly associated with change in BMIZ (Table 3 and
Table S6).
3.2.3 | Body composition at 16 years of age
Without adjustment for n-3 PUFA, GLA (P, trend = .02) and the D6D
index (P, trend = .01) were each positively associated with %ToFM
(Table S6). In fully adjusted models, GLA and the D6D index were
each positively, linearly associated with ToFM, TrFM and %ToFM
(Table 4). Every 1 SD (0.36) difference in GLA was associated with an
adjusted higher mean ToFM (1.0 kg per SD; 95% CI: 0.1, 1.9; P = .03),
TrFM (0.6 kg per SD; 95% CI: 0.1, 1.1; P = .03) and %ToFM (1.0 per-
centage points per SD; 95% CI: 0.2%, 1.7%; P = .01). A 1 SD differ-
ence (0.02) in the D6D index was related to a higher mean ToFM
(1.2 kg per SD; 95% CI: 0.0, 2.3; P = .04), TrFM (0.7 kg per SD; 95%
CI: 0.0, 1.4; P = .05) and %ToFM (1.1 percentage points per SD; 95%
CI: 0.2%, 2.1%; P = .02). The D5D index was inversely associated with
%TrFM. Children in the highest quartile had a mean %TrFM 1.9 per-
centage points lower than did children in the lowest quartile (95% CI:
−3.8%, −0.1%; P = .04). A slight inverse association between DGLA
and %TrFM was present only among girls (P, interaction = .02); no
other associations differed by sex (Tables S7 and S8).
4 | DISCUSSION
In this longitudinal study of Chilean children, PUFA at 1 year of age
were not associated with BMIZ changes through childhood and ado-
lescence. Nevertheless, they were related to body composition at age
16 years. Serum ALA at 1 year of age was positively associated with
TrFM and %TrFM at 16 years. EPA was inversely associated with %
TrFM, while DPA was positively associated with ToFM, TrFM, %
ToFM and %TrFM. GLA and the D6D index were each positively asso-
ciated with ToFM, TrFM and %ToFM. The D5D index was inversely
associated with %TrFM.
Serum ALA was positively associated with truncal fat. This is in
contrast to a previous study in which maternal plasma ALA during
pregnancy was inversely associated with the android/gynoid fat mass
ratio and pre-peritoneal fat mass area in offspring at 6 years of age.33
One potential explanation for this discrepancy is the difference in
ages at which body composition was measured in the two studies.
Body composition may not track completely between childhood and
adolescence. Thus, the relation between early-life ALA and body com-
position at 6 years of age may be different than its relation with body
composition at 16 years. Other possible explanations include the dif-
ferences in timing of exposure assessment, measures of central adi-
posity, or ALA intake between the study populations. Four other
studies of early-life ALA exposure and measures of adiposity have
used BMI as an outcome, which does not distinguish between fat
compartments. None of these found associations between ALA in
cord blood34,35 or breastmilk15,36 with BMI during infancy or child-
hood, consistent with our finding of no association with BMI change.
The mechanism underlying a potential effect of ALA on central adi-
posity is unclear. One possibility is that much of the serum ALA mea-
sured in these children could have been trans ALA. In areas where
hydrogenated oils are present in the food supply, trans ALA repre-
sents a large proportion of total dietary ALA.37 Chile had not banned
trans FA from its food supply at the time of FA measurement in this
study.38 Although few studies have investigated the health effects of
trans ALA, other trans FA have been positively associated with central
adiposity.39 We did not measure trans isomers of ALA and could not
differentiate its effects from those of cis ALA. The association could
also be due to confounding by unmeasured aspects of diet.
We found that EPA was inversely associated with %TrFM. In a
randomized trial, supplementation with EPA + DHA from birth to
6 months resulted in lower waist circumference at 5 years of age.40 In
another study, maternal plasma EPA during pregnancy was inversely
associated with the android/gynoid fat mass ratio and pre-peritoneal
fat mass area at 6 years.33 Previous studies of EPA during pregnancy,
in cord blood, or in breastmilk have not consistently found protective
associations with measures of overall adiposity such as BMI and %
ToFM.13 However, our results and others suggest that EPA may be
specifically protective against central adiposity, which is related to
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TABLE 3 Changes in BMI-for-age Z scores (BMIZ)a from 1 to 16 years of age by serum n-6 polyunsaturated fatty acid biomarkers and
desaturase activity indices at 1 year of age among children from Santiago, Chile
Fatty acid quartile (median,










Q1 (16.53) 159 0.78 ± 0.07 0.56 ± 0.10 −0.23 ± 0.11 Reference
Q2 (21.31) 159 0.72 ± 0.08 0.79 ± 0.09 0.07 ± 0.10 0.34 (0.03, 0.64)
Q3 (25.87) 159 0.80 ± 0.07 0.74 ± 0.09 −0.06 ± 0.09 0.22 (−0.11, 0.54)
Q4 (30.97) 159 0.95 ± 0.08 0.80 ± 0.09 −0.16 ± 0.10 0.11 (−0.27, 0.49)
P, trendd .88 .73
GLA (18:3 n-6)
Q1 (0.00) 159 0.83 ± 0.07 0.64 ± 0.09 −0.18 ± 0.10 Reference
Q2 (0.07) 159 0.87 ± 0.07 0.79 ± 0.09 −0.07 ± 0.10 0.10 (−0.18, 0.37)
Q3 (0.11) 159 0.81 ± 0.08 0.69 ± 0.10 −0.12 ± 0.11 0.05 (−0.25, 0.35)
Q4 (0.42) 159 0.75 ± 0.08 0.75 ± 0.09 0.00 ± 0.09 0.21 (−0.08, 0.49)
P, trend .21 .18
DGLA (20:3 n-6)
Q1 (0.44) 159 0.84 ± 0.08 0.68 ± 0.09 −0.16 ± 0.10 Reference
Q2 (0.61) 159 0.74 ± 0.07 0.84 ± 0.09 0.10 ± 0.10 0.25 (−0.03, 0.53)
Q3 (0.76) 159 0.76 ± 0.07 0.73 ± 0.09 −0.03 ± 0.10 0.13 (−0.15, 0.40)
Q4 (0.96) 159 0.90 ± 0.08 0.63 ± 0.10 −0.27 ± 0.11 −0.12 (−0.41, 0.17)
P, trend .29 .28
AA (20:4 n-6)
Q1 (0.94) 159 0.90 ± 0.07 0.66 ± 0.09 −0.24 ± 0.10 Reference
Q2 (1.31) 159 0.68 ± 0.07 0.68 ± 0.09 0.00 ± 0.10 0.26 (−0.04, 0.56)
Q3 (1.65) 159 0.78 ± 0.07 0.68 ± 0.09 −0.09 ± 0.10 0.22 (−0.10, 0.55)
Q4 (2.27) 159 0.90 ± 0.08 0.86 ± 0.10 −0.04 ± 0.11 0.32 (−0.04, 0.68)
P, trend .29 .13
N-6:N-3 ratio
Q1 (12.7:1) 159 0.88 ± 0.08 0.78 ± 0.09 −0.10 ± 0.11 Reference
Q2 (18.3:1) 159 0.71 ± 0.08 0.66 ± 0.09 −0.04 ± 0.10 0.06 (−0.22, 0.35)
Q3 (22.9:1) 159 0.81 ± 0.07 0.74 ± 0.10 −0.07 ± 0.10 0.06 (−0.23, 0.35)
Q4 (32.0:1) 159 0.85 ± 0.07 0.70 ± 0.09 −0.15 ± 0.09 0.00 (−0.28, 0.29)
P, trend .63 .96
Desaturase activity indices
Δ6-Desaturase index (GLA/LA)
Q1 (0.000) 159 0.85 ± 0.08 0.63 ± 0.08 −0.22 ± 0.10 Reference
Q2 (0.003) 159 0.81 ± 0.07 0.84 ± 0.10 0.03 ± 0.11 0.22 (−0.06, 0.50)
Q3 (0.005) 159 0.85 ± 0.07 0.66 ± 0.09 −0.19 ± 0.11 0.02 (−0.27, 0.31)
Q4 (0.017) 159 0.74 ± 0.08 0.76 ± 0.09 0.01 ± 0.09 0.24 (−0.04, 0.52)
P, trend .19 .18
Δ5-Desaturase index (AA/DGLA)
Q1 (1.57) 159 0.83 ± 0.07 0.63 ± 0.09 −0.20 ± 0.10 Reference
Q2 (1.94) 159 0.76 ± 0.07 0.66 ± 0.09 −0.10 ± 0.10 0.05 (−0.22, 0.33)
Q3 (2.42) 159 0.84 ± 0.07 0.88 ± 0.09 0.04 ± 0.11 0.13 (−0.17, 0.43)
Q4 (3.21) 159 0.83 ± 0.08 0.71 ± 0.09 −0.11 ± 0.10 0.01 (−0.31, 0.32)
P, trend .54 .99
aAccording to the World Health Organization Growth Reference for children ages 5 to 19 years.25
bFrom growth curves estimated using mixed effects linear regression models with BMI as the outcome, and predictors that included indicator variables for
each PUFA quartile, linear and cubic spline terms for age and interaction terms between the quartiles and age terms. All models included random intercepts
and age slopes to account for within-child correlations of repeated BMI measurements.
cAdjusted for sex, birth weight (large vs average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indica-
tor variables for quintiles) and total serum trans fatty acids. All n-6 PUFA are adjusted for ALA and total long-chain n-3 PUFA. All long chain PUFA are
adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.
dFrom mixed effects linear regression models with BMI as the outcome and a variable representing medians of PUFA quartiles introduced as continuous.
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development of the metabolic syndrome41 and cardiovascular dis-
ease.42 Whether early-life EPA decreases risk of future chronic dis-
ease remains to be investigated.
DPA at age 1 year was positively associated with ToFM, TrFM, %
ToFM and %TrFM at 16 years. In a pooled analysis of two large
cohorts, cord blood DPA was not associated with childhood BMI.43
Maternal DPA during pregnancy was inversely associated with %
ToFM and the android/gynoid fat mass ratio at 6 years in a Dutch
study.33 Compared with EPA, DPA is found at lower levels in the
diet44 and may be less bioavailable.45 Thus, DPA in serum could more
closely reflect endogenous activity of D6D than it does DPA intake.
Associations between DPA and fat mass might reflect associations
with D6D activity rather than an effect of DPA itself.
GLA was positively associated with ToFM, TrFM and %ToFM.
This is in agreement with an investigation that reported a positive
association between maternal plasma GLA during pregnancy and %
ToFM and pre-peritoneal fat mass area in offspring at age 6 years.33
However, two other studies found no association between cord blood
GLA and BMI or %ToFM in childhood.43,46 A trial of formula sup-
plemented with GLA + DHA until 9 months of age found no effect on
BMI or %ToFM at age 10 years.47 Differences among studies may be
the result of differences in GLA levels between populations, or effect
modification by desaturase gene variations.48
Estimated D6D enzyme activity was positively associated with
ToFM, TrFM and %ToFM, while the D5D index was inversely associ-
ated with %TrFM. Our results are consistent with two longitudinal
studies conducted among children aged 2 to 10 years49 and
10 years,50 and evidence that cardiometabolic risk factors are posi-
tively related to D6D activity and inversely associated with D5D
activity among adults.51
Although PUFA in infancy were related to body composition in
adolescence, they were not associated with BMIZ trajectories. These
results are unexpected since BMI and BMIZ correlate with fat mass
throughout childhood. One possible explanation is that the differ-
ences in body composition at 16 years by PUFA concentrations may
already have been present at 1 year. We tried to overcome this possi-
bility by adjusting the analyses of body composition measures at age
16 years for BMI at 1 year, but BMI in infancy is an imperfect proxy
for fat mass. Another possibility is that the outcomes measured by
DXA are more precise measures of adiposity than BMIZ, which
reflects both fat and lean mass, or that the effects of PUFA differ
between body fat compartments, which are not separated by
using BMIZ.
One of the primary strengths of this study is its longitudinal
design, which limits the possibility of reverse causation. We had an
opportunity to examine associations of early-life exposures with out-
comes at older ages, which provides evidence for the relevance of
PUFA status in infancy for long-term health. PUFA biomarkers are not
subject to errors in recall or food composition tables, as opposed to
dietary assessment data. Furthermore, we assessed body composition
using DXA, which provides reliable and valid measures of fat and lean
mass.52
One of the limitations of this study is that serum PUFA bio-
markers reflect status over a period of weeks and may misclassify par-
ticipants with respect to long-term intake.53 Analyses of multiple
exposures could have increased type I error. Body composition mea-
sures differ by sex in adolescence54; although interactions by sex
were not statistically significant, effect modification by sex cannot be
completely ruled out. The lack of available body composition mea-
surements in infancy prevented us from analyzing change in these
outcomes or adjusting for their baseline values. Adiposity at 1 year of
age could have influenced serum PUFA levels at 1 year of age, and
this reverse causation may have influenced the results related to
BMIZ trajectories. However, we chose not to adjust for baseline BMIZ
in these analyses because this adjustment can cause bias.55 Measured
baseline BMIZ is the result of both true baseline BMIZ and its measure-
ment error, which in turn contributes to measured BMIZ change from
baseline to 16 years, the outcome of interest. As a common effect of
two variables (a “collider”), baseline BMIZ naturally blocks the flow of a
non-causal statistical association between the exposure (PUFA) and the
outcome. Adjusted for baseline BMIZ could unblock such a non-causal
path and induce a spurious association between PUFA and BMIZ
change from baseline to later ages. Finally, because we only had rela-
tive measures of serum PUFA expressed as a percentage of total FA,
we were unable to determine the extent to which differences in PUFA
FA percentage reflect differences in absolute serum PUFA content or
serum levels of saturated, monounsaturated and trans FA.
In conclusion, serum ALA and DPA at 1 year of age were posi-
tively associated with measures of fat mass at age 16 years, whereas
EPA was inversely associated with %TrFM. GLA and the D6D index
were also positively associated with adiposity in adolescence, while
D5D activity was inversely related to this outcome. PUFA status in
infancy might affect long-term body composition and adiposity. Our
results could be generalizable to other populations with similar dietary
intake and behaviour, which in this Chilean population have been
characterized as low in fruits and vegetables, high in snack foods with
saturated fat and refined carbohydrates and low in physical activity
levels.56 Our results may also be applicable to populations undergoing
a similar nutrition transition. In Chile, economic growth in the 1990s
resulted in one of the most rapid transitions in Latin America, includ-
ing a shift towards Western diets and sedentary lifestyles.57 By the
time of the 16 years follow-up in our study, the transition was
advanced with a very low prevalence of stunting and high prevalence
of obesity.58 Intervention studies are warranted to elucidate the
potential protective effect of EPA against the development of central
adiposity in children and adolescents.
ACKNOWLEDGMENTS
EV, SG and BL designed the research. SG, BL and AD conducted the
research. KF performed the data analysis. KF and EV wrote the paper
and had primary responsibility for the final content. All authors read
and approved the final manuscript.
The study was funded by grants HL117860, HD033487 and
HL088530 from the National Institutes of Health. Fatty acids were
FLANNAGAN ET AL. 11 of 13
quantified using Core Services supported by grant DK097153 from
the National Institutes of Health to the University of Michigan.
CONFLICT OF INTEREST





1. Park MH, Falconer C, Viner RM, Kinra S. The impact of childhood
obesity on morbidity and mortality in adulthood: a systematic review.
Obes Rev. 2012;13(11):985-1000.
2. (NCD-RisC) NRFC. Worldwide trends in body-mass index, under-
weight, overweight, and obesity from 1975 to 2016: a pooled analysis
of 2416 population-based measurement studies in 128.9 million chil-
dren, adolescents, and adults. Lancet. 2017;390(10113):2627-2642.
3. Buckley JD, Howe PR. Anti-obesity effects of long-chain omega-3
polyunsaturated fatty acids. Obes Rev. 2009;10(6):648-659.
4. Leikin-Frenkel A, Shomonov-Wagner L, Juknat A, Pasmanik-Chor M.
Maternal diet enriched with alpha-Linolenic or saturated fatty acids
differentially regulates gene expression in the liver of mouse off-
spring. J Nutrigenet Nutrigenomics. 2015;8(4–6):185-194.
5. Muhlhausler BS, Ailhaud GP. Omega-6 polyunsaturated fatty acids
and the early origins of obesity. Curr Opin Endocrinol Diabetes Obes.
2013;20(1):56-61.
6. Martinez-Victoria E, Yago MD. Omega 3 polyunsaturated fatty acids
and body weight. Br J Nutr. 2012;107(Suppl 2):S107-S116.
7. Naughton SS, Mathai ML, Hryciw DH, McAinch AJ. Linoleic acid and
the pathogenesis of obesity. Prostaglandins Other Lipid Mediat. 2016;
125:90-99.
8. Hooper L, Al-Khudairy L, Abdelhamid AS, et al. Omega-6 fats for the
primary and secondary prevention of cardiovascular disease. Cochrane
Database Syst Rev. 2018;11:Cd011094.
9. Shils ME, Shike M. Modern Nutrition in Health and Disease. Philadel-
phia, PA: Lippincott Williams & Wilkins; 2006.
10. Carlson SE, Colombo J. Docosahexaenoic acid and Arachidonic acid
nutrition in early development. Adv Pediatr. 2016;63(1):453-471.
11. Kinra S, Rameshwar Sarma KV, Ghafoorunissa, et al. Effect of integra-
tion of supplemental nutrition with public health programmes in preg-
nancy and early childhood on cardiovascular risk in rural Indian
adolescents: long term follow-up of Hyderabad nutrition trial. BMJ.
2008;337:a605.
12. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turn-
over in humans. Nature. 2008;453(7196):783-787.
13. Voortman T, van den Hooven EH, Braun KV, et al. Effects of polyun-
saturated fatty acid intake and status during pregnancy, lactation, and
early childhood on cardiometabolic health: a systematic review. Prog
Lipid Res. 2015;59:67-87.
14. Stein AD, Wang M, Martorell R, et al. Growth to age 18 months fol-
lowing prenatal supplementation with docosahexaenoic acid differs
by maternal gravidity in Mexico. J Nutr. 2011;141(2):316-320.
15. Tinoco SM, Sichieri R, Setta CL, Moura AS, Carmo MG. N-3 polyun-
saturated fatty acids in milk is associate to weight gain and growth in
premature infants. Lipids Health Dis. 2009;8:23.
16. van der Merwe LF, Moore SE, Fulford AJ, et al. Long-chain PUFA sup-
plementation in rural African infants: a randomized controlled trial of
effects on gut integrity, growth, and cognitive development. Am J Clin
Nutr. 2013;97(1):45-57.
17. Petrova S, Dimitrov P, Willett WC, Campos H. The global availability
of n-3 fatty acids. Public Health Nutr. 2011;14(7):1157-1164.
18. Lozoff B, De Andraca I, Castillo M, Smith JB, Walter T, Pino P. Behav-
ioral and developmental effects of preventing iron-deficiency anemia
in healthy full-term infants. Pediatrics. 2003;112(4):846-854.
19. Roncagliolo M, Garrido M, Walter T, Peirano P, Lozoff B. Evidence of
altered central nervous system development in infants with iron defi-
ciency anemia at 6 mo: delayed maturation of auditory brainstem
responses. Am J Clin Nutr. 1998;68(3):683-690.
20. Burrows R, Correa-Burrows P, Reyes M, Blanco E, Albala C,
Gahagan S. High cardiometabolic risk in healthy Chilean adolescents:
associations with anthropometric, biological and lifestyle factors. Pub-
lic Health Nutr. 2016;19(3):486-493.
21. Matthan NR, Ip B, Resteghini N, Ausman LM, Lichtenstein AH. Long-
term fatty acid stability in human serum cholesteryl ester, triglyceride,
and phospholipid fractions. J Lipid Res. 2010;51(9):2826-2832.
22. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purifi-
cation. Can J Biochem Physiol. 1959;37(8):911-917.
23. Morrison WR, Smith LM. Preparation of fatty acid methyl esters and
dimethylacetals from lipids with boron fluoride–methanol. J Lipid Res.
1964;5:600-608.
24. Rudolph MC, Jackman MR, Presby DM, et al. Low neonatal plasma n-
6/n-3 PUFA ratios regulate offspring Adipogenic potential and condi-
tion adult obesity resistance. Diabetes. 2018;67(4):651-661.
25. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J.
Development of a WHO growth reference for school-aged children
and adolescents. Bull World Health Organ. 2007;85(9):660-667.
26. Villar J, Cheikh Ismail L, Victora CG, et al. International standards for
newborn weight, length, and head circumference by gestational age
and sex: the newborn cross-sectional study of the INTERGROWTH-
21st project. Lancet. 2014;384(9946):857-868.
27. Alvarez ML, Muzzo S, Ivanovic D. Scale for measurement of socioeco-
nomic level, in the health area. Rev Med Chil. 1985;113(3):243-249.
28. Thompson AK, Minihane AM, Williams CM. Trans fatty acids and
weight gain. Int J Obes. 2011;35(3):315-324.
29. Perng W, Mora-Plazas M, Marin C, Villamor E. Iron status and linear
growth: a prospective study in school-age children. Eur J Clin Nutr.
2013;67(6):646-651.
30. Durrleman S, Simon R. Flexible regression models with cubic splines.
Stat Med. 1989;8(5):551-561.
31. Baylin A, Mora-Plazas M, Cobos-de Rangel O, Lopez-Arana S,
Campos H, Villamor E. Predictors of usage and fatty acid composition
of cooking fats in Bogotak, Colombia. Public Health Nutr. 2009;12(4):
531-537.
32. White H. A Heteroskedasticity-consistent covariance-matrix estima-
tor and a direct test for Heteroskedasticity. Econometrica. 1980;48(4):
817-838.
33. Vidakovic AJ, Gishti O, Voortman T, et al. Maternal plasma PUFA con-
centrations during pregnancy and childhood adiposity: the generation
R study. Am J Clin Nutr. 2016;103(4):1017-1025.
34. Donahue SM, Rifas-Shiman SL, Gold DR, Jouni ZE, Gillman MW,
Oken E. Prenatal fatty acid status and child adiposity at age 3 y:
results from a US pregnancy cohort. Am J Clin Nutr. 2011;93(4):
780-788.
35. Helland IB, Smith L, Blomen B, Saarem K, Saugstad OD, Drevon CA.
Effect of supplementing pregnant and lactating mothers with n-3
very-long-chain fatty acids on children's IQ and body mass index at
7 years of age. Pediatrics. 2008;122(2):e472-e479.
36. Scholtens S, Wijga AH, Smit HA, et al. Long-chain polyunsaturated
fatty acids in breast milk and early weight gain in breast-fed infants.
Br J Nutr. 2009;101(1):116-121.
37. Wolff R. trans-polyunsaturated fatty acids in French edible rapeseed
and soybean oils. J Am Oil Chem Soc. 1992;69(2):106-110.
38. Colon-Ramos U, Monge-Rojas R, Campos H. Impact of WHO recom-
mendations to eliminate industrial trans-fatty acids from the food
supply in Latin America and the Caribbean. Health Policy Plan. 2014;
29(5):529-541.
12 of 13 FLANNAGAN ET AL.
39. Micha R, Mozaffarian D. Trans fatty acids: effects on metabolic syn-
drome, heart disease and diabetes. Nat Rev Endocrinol. 2009;5(6):
335-344.
40. See VHL, Mori TA, Prescott SL, Beilin LJ, Burrows S, Huang RC. Car-
diometabolic risk factors at 5 years after Omega-3 fatty acid supple-
mentation in infancy. Pediatrics. 2018;142(1):e20162623.
41. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syn-
drome. Lancet. 2010;375(9710):181-183.
42. de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference
and waist-to-hip ratio as predictors of cardiovascular events: meta-
regression analysis of prospective studies. Eur Heart J. 2007;28(7):
850-856.
43. Stratakis N, Gielen M, Margetaki K, et al. Polyunsaturated fatty acid
status at birth, childhood growth, and cardiometabolic risk: a pooled
analysis of the MEFAB and RHEA cohorts. Eur J Clin Nutr. 2019;73(4):
566-576.
44. Kaur G, Guo XF, Sinclair AJ. Short update on docosapentaenoic acid:
a bioactive long-chain n-3 fatty acid. Curr Opin Clin Nutr Metab Care.
2016;19(2):88-91.
45. Ghasemi Fard S, Linderborg KM, Turchini GM, Sinclair AJ. Compari-
son of the bioavailability of docosapentaenoic acid (DPA, 22:5n-3)
and eicosapentaenoic acid (EPA, 20:5n-3) in the rat. Prostaglandins
Leukot Essent Fatty Acids. 2014;90(1):23-26.
46. Rump P, Popp-Snijders C, Heine RJ, Hornstra G. Components of the
insulin resistance syndrome in seven-year-old children: relations with
birth weight and the polyunsaturated fatty acid content of umbilical
cord plasma phospholipids. Diabetologia. 2002;45(3):349-355.
47. Kennedy K, Ross S, Isaacs EB, et al. The 10-year follow-up of a
randomised trial of long-chain polyunsaturated fatty acid supplemen-
tation in preterm infants: effects on growth and blood pressure. Arch
Dis Child. 2010;95(8):588-595.
48. Murff HJ, Edwards TL. Endogenous production of long-chain polyun-
saturated fatty acids and metabolic disease risk. Curr Cardiovasc Risk
Rep. 2014;8(12):418.
49. Wolters M, Schlenz H, Bornhorst C, et al. Desaturase activity is asso-
ciated with weight status and metabolic risk markers in young chil-
dren. J Clin Endocrinol Metab. 2015;100(10):3760-3769.
50. Abe Y, Okada T, Iguchi H, et al. Association of changes in body fat-
ness and fatty acid composition of plasma phospholipids during early
puberty in Japanese children. J Atheroscler Thromb. 2012;19(12):
1102-1109.
51. Tosi F, Sartori F, Guarini P, Olivieri O, Martinelli N. Delta-5 and
delta-6 desaturases: crucial enzymes in polyunsaturated fatty acid-
related pathways with pleiotropic influences in health and disease.
Adv Exp Med Biol. 2014;824:61-81.
52. Helba M, Binkovitz LA. Pediatric body composition analysis with dual-
energy X-ray absorptiometry. Pediatr Radiol. 2009;39(7):647-656.
53. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose
tissue and blood in humans and its use as a biomarker of dietary
intake. Prog Lipid Res. 2008;47(5):348-380.
54. Ripka WL, Orsso CE, Haqq AM, Luz TG, Prado CM, Ulbricht L. Lean
mass reference curves in adolescents using dual-energy x-ray absorp-
tiometry (DXA). PLoS One. 2020;15(2):e0228646.
55. Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM. When is
baseline adjustment useful in analyses of change? An example with
education and cognitive change. Am J Epidemiol. 2005;162(3):267-278.
56. Olivares S, Kain J, Lera L, Pizarro F, Vio F, Moron C. Nutritional status,
food consumption and physical activity among Chilean school chil-
dren: a descriptive study. Eur J Clin Nutr. 2004;58(9):1278-1285.
57. Albala C, Vio F, Kain J, Uauy R. Nutrition transition in Chile: determi-
nants and consequences. Public Health Nutr. 2002;5(1a):123-128.
58. Atalah E, Amigo H, Bustos P. Does Chile's nutritional situation consti-
tute a double burden? Am J Clin Nutr. 2014;100(6):1623s–1627s.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Flannagan K, Gahagan S, Das A,
Burrows R, Lozoff B, Villamor E. Serum polyunsaturated fatty
acids in infancy are associated with body composition in
adolescence. Pediatric Obesity. 2020;15:e12656. https://doi.
org/10.1111/ijpo.12656
FLANNAGAN ET AL. 13 of 13
